SG Americas Securities LLC Increases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

SG Americas Securities LLC raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 132.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,126 shares of the company's stock after buying an additional 8,043 shares during the quarter. SG Americas Securities LLC's holdings in TransMedics Group were worth $950,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. State of Michigan Retirement System acquired a new position in shares of TransMedics Group in the fourth quarter valued at approximately $6,734,000. Peregrine Capital Management LLC grew its stake in TransMedics Group by 64.0% in the 4th quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock worth $4,124,000 after acquiring an additional 25,814 shares during the period. Oppenheimer & Co. Inc. raised its holdings in TransMedics Group by 41.3% in the 4th quarter. Oppenheimer & Co. Inc. now owns 63,424 shares of the company's stock valued at $3,954,000 after acquiring an additional 18,531 shares during the last quarter. Emerald Advisers LLC lifted its stake in shares of TransMedics Group by 146.3% during the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock worth $23,176,000 after purchasing an additional 220,804 shares during the period. Finally, Capital Fund Management S.A. lifted its stake in shares of TransMedics Group by 940.3% during the 4th quarter. Capital Fund Management S.A. now owns 125,880 shares of the company's stock worth $7,849,000 after purchasing an additional 113,780 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on TMDX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler restated an "overweight" rating and issued a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Tuesday. Finally, Oppenheimer boosted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus price target of $127.33.

Insider Activity at TransMedics Group

In other news, Director David Weill sold 732 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the sale, the director now owns 12,134 shares in the company, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider now owns 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,418 shares of company stock worth $1,512,613. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Trading Down 9.0%

Shares of NASDAQ:TMDX traded down $12.20 during trading on Thursday, reaching $124.00. 2,096,632 shares of the stock were exchanged, compared to its average volume of 1,366,337. The firm's 50-day moving average price is $112.41 and its 200 day moving average price is $83.42. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of 91.18 and a beta of 2.10. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The firm had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. During the same period in the previous year, the company posted $0.35 earnings per share. TransMedics Group's revenue was up 48.2% compared to the same quarter last year. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.